Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Regeneron Pharmaceuticals is a biotech company headquartered in New York. While it works on a number of drugs and diseases, it's most recently been in the news for REGN-COV2 — the experimental antibody cocktail.
The antibody cocktail is being studied as a possible treatment for the novel coronavirus. Most notably, it was reported that President Trump was given REGN-COV2 after his COVID-19 diagnosis. But Trump received the drug under a Compassionate Use request, which means it's not yet FDA cleared and is still highly experimental.
Whether or not this drug proves to be effective in treating the novel coronavirus may have a significant impact on Regeneron's stock prices. With so many companies working on COVID-19 cures, vaccines and prophylactics, it's a race to see which drugs are approved first — and which turn out to be the most successful.
After news broke that President Trump had been given Regeneron’s experimental COVID-19 treatment, REGN-COV2, the company’s stock rose 7%. This increase brings the stock’s year-to-date gain to more than 60% as of early October.
Excitement over the company’s COVID-19 treatment is buffeting share prices, but REGN-COV2 has not yet been approved by the Food and Drug Administration (FDA). The treatment was administered to President Trump under a Compassionate Use request.
REGN-COV2 is Regeneron’s experimental COVID-19 treatment. It’s a combination of two antibodies designed to help the immune system recover from illness.
The treatment is still in clinical testing but reported encouraging results from its Phase 1/2/3 study. In this study, 275 trial patients were given REGN-COV2. Administration of the antibody cocktail resulted in a reduction in viral load and time to alleviate symptoms in non-hospitalized patients afflicted with COVID-19.
Side effects were reported in two patients, but those patients were taking placebos, according to Regeneron.
In July 2020, Regeneron signed a supply agreement for REGN-COV2 with the US government worth $450 million as part of the president’s Operation Warp Speed plan to develop COVID-19 treatments and vaccines.
Since the stock market crash in March caused by coronavirus, Regeneron Pharmaceuticals's share price has had significant positive movement.
Its last market close was USD$599.74, which is 32.78% up on its pre-crash value of USD$403.15 and 76.71% up on the lowest point reached during the March crash when the shares fell as low as USD$339.39.
If you had bought USD$1,000 worth of Regeneron Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$1,335.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,757.24.
|Latest market close||USD$599.74|
|52-week range||USD$328.125 - USD$664.64|
|50-day moving average||USD$568.0559|
|200-day moving average||USD$592.3193|
|Wall St. target price||USD$673.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$27.286|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-19)||16.52%|
|1 month (2020-10-27)||2.96%|
|3 months (2020-08-27)||-2.48%|
|6 months (2020-05-27)||10.24%|
|1 year (2019-11-26)||64.84%|
|2 years (2018-11-26)||69.81%|
|3 years (2017-11-24)||55.84%|
|5 years (2015-11-25)||6.77%|
Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Regeneron Pharmaceuticals shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0912. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$3.3 billion.
The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$9.2 billion|
|Operating margin TTM||33.76%|
|Gross profit TTM||USD$4 billion|
|Return on assets TTM||12.99%|
|Return on equity TTM||30.6%|
|Market capitalisation||USD$54 billion|
TTM: trailing 12 months
There are currently 2.2 million Regeneron Pharmaceuticals shares held short by investors – that's known as Regeneron Pharmaceuticals's "short interest". This figure is 7.1% down from 2.3 million last month.
There are a few different ways that this level of interest in shorting Regeneron Pharmaceuticals shares can be evaluated.
Regeneron Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Regeneron Pharmaceuticals shares currently shorted divided by the average quantity of Regeneron Pharmaceuticals shares traded daily (recently around 862939.0438247). Regeneron Pharmaceuticals's SIR currently stands at 2.51. In other words for every 100,000 Regeneron Pharmaceuticals shares traded daily on the market, roughly 2510 shares are currently held short.
However Regeneron Pharmaceuticals's short interest can also be evaluated against the total number of Regeneron Pharmaceuticals shares, or, against the total number of tradable Regeneron Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Regeneron Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Regeneron Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0261% of the tradable shares (for every 100,000 tradable Regeneron Pharmaceuticals shares, roughly 26 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Regeneron Pharmaceuticals.
Find out more about how you can short Regeneron Pharmaceuticals stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Regeneron Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 22.33
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Regeneron Pharmaceuticals's overall score of 22.33 (as at 01/01/2019) is pretty good – landing it in it in the 27th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Regeneron Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.51/100
Regeneron Pharmaceuticals's environmental score of 1.51 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 13.94/100
Regeneron Pharmaceuticals's social score of 13.94 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 5.88/100
Regeneron Pharmaceuticals's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Regeneron Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Regeneron Pharmaceuticals has, for the most part, managed to keep its nose clean.
|Total ESG score||22.33|
|Total ESG percentile||26.82|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||2|
We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Regeneron Pharmaceuticals's shares have ranged in value from as little as $328.125 up to $664.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.3968. This would suggest that Regeneron Pharmaceuticals's shares are less volatile than average (for this exchange).
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Steps to owning and managing SELF, with 24-hour and historical pricing before you buy.
Steps to owning and managing GLP, with 24-hour and historical pricing before you buy.
Steps to owning and managing FRGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXFO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ESRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLOW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FOF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing CGNX, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.